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Crimean-Congo haemorrhagic fever (CCHF) is an 
infectious viral disease that has (re-)emerged in the 
last decade in south-eastern Europe, and there is a 
risk for further geographical expansion to western 
Europe. Here we report the results of a survey cov-
ering 28 countries, conducted in 2012 among the 
member laboratories of the European Network for 
Diagnostics of ‘Imported’ Viral Diseases (ENIVD) to 
assess laboratory preparedness and response capaci-
ties for CCHF. The answers of 31 laboratories of the 
European region regarding CCHF case definition, train-
ing necessity, biosafety, quality assurance and diag-
nostic tests are presented. In addition, we identified 
the lack of a Regional Reference Expert Laboratory in 
or near endemic areas. Moreover, a comprehensive 
review of the biosafety level suitable to the reality of 
endemic areas is needed. These issues are challenges 
that should be addressed by European public health 
authorities. However, all respondent laboratories have 
suitable diagnostic capacities for the current situation.
Introduction
Crimean-Congo haemorrhagic fever (CCHF) is a zoonotic 
viral disease caused by the tick-borne CCHF virus 
(CCHFV), which is classified into the genus Nairovirus 
within the Bunyaviridae family. In humans, the dis-
ease is highly pathogenic and life-threatening as it 
can cause severe illness with prominent haemorrhages 
reaching case fatality rates of up to 50%. In nature, 
CCHFV usually circulates between asymptomatic ani-
mals and ticks in an enzootic cycle. Humans may 
become infected through the bite of a tick, mainly of the 
Hyalomma genus, through direct contact with blood or 
tissues from viraemic livestock or through direct con-
tact with the blood or secretions of a viraemic patient 
[1]. Thus, risk groups include individuals with outdoor 
activities, mainly those who have occupational contact 
with animals, as well as healthcare workers in hospital 
settings (nosocomial hazard). Because of the potential 
for epidemics and nosocomial outbreaks, high fatal-
ity ratio, limitations for treatment and the lack of safe 
vaccine, CCHF is a disease listed for immediate notifi-
cation to public health authorities as it constitutes a 
major threat to public health. Therefore, CCHFV is con-
sidered a high-risk pathogenic organism and classified 
as a biosafety level (BSL) 4 containment agent.
The disease is endemic in wide areas of Africa, the 
Middle East, central and south-western Asia and the 
south-eastern European region. More particularly, 
some Balkan countries (e.g. Albania, Bulgaria, Greece 
and Kosovo under UN Security Council Resolution 
1244) are endemic zones for CCHF [2]. During the last 
decade, CCHF re-emerged in Albania, Greece, Kosovo 
under UN Security Council Resolution 1244 and coun-
tries bordering the Black sea: Georgia, south-western 
Russia Turkey, and Ukraine. In Greece, the detection 
of the non-pathogenic strain AP92 in ticks in 1975 was 
followed by the notification of the first human CCHF 
case in June 2008 [3]. However, the vast majority of 
CCHF cases have been recorded in Turkey (since 2002) 
and the south-western regions of Russia (since 1999), 
with expanding outbreaks and increasing numbers of 
associated fatalities [2]. In northern and south-western 
Europe, no human cases have been reported except 
for imported ones in France [4], Germany [5] and the 
United Kingdom [6]. Limited serological evidence in 
humans has been reported in parts of Hungary and 
Portugal [7,8].
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In Europe, the tick vector most commonly associated 
with CCHFV is Hyalomma marginatum, which is present 
in southern Europe and has sporadically been detected 
in southern Germany, the Netherlands and the United 
Kingdom following expansion of its geographical range 
associated with movement of migrant breeding birds 
[9-12]. The spreading of the vector represents a risk 
factor for introduction of the virus from endemic to 
unaffected areas of Europe, increasing the occurrence 
of CCHF [13]. However, virological evidence has never 
been addressed in western Europe until 2010, when 
a study conducted in Spain detected for the first time 
CCHFV in populations of H. lusitanicum collected from 
indigenous deer [14]. Moreover, the recent discovery 
of antibodies against CCHFV in livestock in Romania, 
with prevalence values similar to those observed in 
other regions where the disease is endemic, suggests 
an extension of the circulation zone of CCHFV in Europe 
[15].
In 2008, after the first case in Greece was detected, 
the European Centre for Disease Prevention and 
Control (ECDC) organised an expert consultation on 
CCHF to identify preparedness interventions in Europe 
[13]. In 2011, under the initiative of the European 
Network for Diagnostics of ‘Imported’ Viral Diseases 
(ENIVD; www.enivd.org), a multicenter study of CCHF 
diagnostic tests and an external quality assessment 
Table 1
ENIVD survey on Crimean-Congo haemorrhagic fever, responding laboratories, by country, 2012 (n=31)
Participating countries Participating laboratories Acts as NRL WHOCC
Austria Medical University of Vienna, Vienna No No
Belgium Institute of Tropical Medicine,  Antwerpen Yes No
Bulgaria National Centre for Infectious and Parasitic Diseases, Sofia Yes No
Croatia University Hospital for Infectious Diseases, Zagreb No No
Czech Republic Institute of Public Health, Ostrava No No
Estonia National Institute for Health Development/Health Board, Tallinn No No
Former Yugoslav Republic 
of Macedonia Institute of Health Protection of the FYROM No No
France
1. Institut Pasteur, Lyon Yes Yes
2. Aix-Marseille University and AP-HM Public Hospitals, Marseille No No
Germany
1. Bernhard-Nocht Institut, Hamburg Yes Yes
2. Institut für Mikrobiologie der Bundeswehr, Munich No No
Greece Aristotle University, Thessaloniki Yes
No 
(discontinued 
since 20/
Oct/2008)a
Italy National Institute for Infectious Diseases “L.Spallanzani”, Rome Yes Yes
Kosovo under UN Security 
Council Resolution 1244 National Institute of Public Health of Kosovo, Pristina Yes No
Latvia Infectology Center of Latvia, Riga Yes No
Lithuania National Public Health Surveillance Laboratory, Vilnius Yes No
Malta Mater Dei Hospital, Valletta No No
The Netherlands Erasmus University Hospital, Rotterdam Yes Yes
Norway Norwegian Institute of Public Health, Oslo Yes No
Portugal National Institute of Health, Águas de Moura Yes No
Romania National Institute of Public Health, Bucharest Yes No
Russia Central Research Institute of Epidemiology, Moscow Yes No
Serbia Torlak Institute of Virology, Belgrade Yes No
Slovakia Institute of Virology, Slovak Academy of Sciences, Bratislava No No
Slovenia University of Ljubljana, Ljubljana Yes
No 
(discontinued 
since 1/
Sep/2008)a
Spain Instituto de Salud Carlos III, Madrid Yes No
Sweden Swedish Institute for Infectious Disease Control, Karolinska Institute Stockholm, Solna Yes No
Switzerland University Hospitals of Geneva, Geneva Yes No
Turkey Refik Saydam Hygiene Institute, Ankara Yes No
United Kingdom
1. Public Health England, Colindale No No
2. Public Health England, Porton Down Yes Yes
ENIVD: European Network for Diagnostics of ‘Imported’ Viral Diseases; NRL: National Reference Laboratory; WHOCC: World Health 
Organization Collaborating Center (http://apps.who.int/whocc/ ) for Viral Haemorrhagic Fevers from the EURO region.
a Discontinued means that the institution is no longer a WHOCC.
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(EQA) for CCHF molecular diagnosis were carried out to 
monitor and compare the performance of the different 
techniques applied for diagnosis of CCHF [16,17]. The 
current situation with continous high transmission in 
Turkey and south-western Russia, new imported cases 
in the European Union (EU), detection of the virus for 
the first time in the western Mediterranean region, 
and new evidence of seroprevalence in animals, make 
necessary a new assessment on preparedness and 
laboratory capacities for CCHF in the European region. 
Here, we describe the results of a questionnaire survey 
conducted in 2012 to assess the laboratory prepared-
ness and response capacities for CCHF diagnosis in the 
European region.
Methods
To gather information on CCHF diagnostics, prepared-
ness and response capacities in Europe, a question-
naire was developed and sent electronically in January 
2012 to laboratory contact points in the ENIVD data-
base, covering 28 Member States of the EU as well as 
nine non-EU countries, Russia, Norway, Switzerland, 
Bosnia and Herzegovina, Serbia, Kosovo under UN 
Security Council Resolution 1244, Albania, the Former 
Yugoslavia Republic of Macedonia and Turkey. All 
completed questionnaires were received by April 2012. 
The first part of the questionnaire assessed prepared-
ness and response capacities, while the second part 
was designed to collect information on diagnostic 
capacities and quality assurance. Questions on the fol-
lowing topics were included in the questionnaire: CCHF 
case definition, training necessity, biosafety assur-
ance, diagnostic tests and quality assurance. The list 
of respondents is shown in Table 1. Respondents were 
National Reference Laboratories (NRL) for Arbovirus 
and Viral Haemorrhagic Fever (VHF) and/or World 
Health Organization Collaborating Centers (WHOCC). 
An NRL was defined as a laboratory involved in recep-
tion/management of suspected samples of CCHF, either 
for diagnostic and reference activities or for shipment 
abroad in case of lack diagnostic capacity
Results
Participation
Sixty-eight laboratories from 37 countries (28 EU 
Members States and nine countries outside the EU), 
were contacted for this survey. Thirty-one laborato-
ries from 28 countries returned their answer, except 
Albania, Bosnia and Herzegovina, Cyprus, Denmark, 
Figure 1
Diagnostic capacities and occurrence of Crimean-Congo haemorrhagic fever in Europe since 2000
i
i
i
i
Available only MOLECULAR methods 
Countries without responding laboratories 
Available MOLECULAR and SEROLOGICAL methods 
NO methods: send samples outside country 
Available only SEROLOGICAL methods 
CCHF serological evidence in humans 
CCHF serological evidence in animals 
CCHF virological evidence in ticks 
CCHF human imported cases 
≥ 1 CCHF human cases 
> 100 CCHF human cases 
> 1,000 CCHF human cases 
Current limit for geographic distribution of  
genus Hyalomma ticks 
Countries did not participate in the survey 
CCHF: Crimean-Congo haemorrhagic fever; ECDC: European Centre for Disease Prevention and Control; WHO: World Health Organization.
Colour code indicates diagnostic capacities as assessed in the present survey. Human silhouettes indicate occurrence of CCHF in humans 
according to the WHO database (http://data.euro.who.int/cisid), the ECDC consultation [13] and the Public Health England database (http://
www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/CCHF/EpidemiologicalData/cchfoutbreaks/). Tick silhouettes indicate virological 
evidence of CCHF in ticks in those countries where no human cases have been reported. Antibody silhouettes indicate serological evidence 
of CCHF in humans or animals in countries where no human cases have been reported. 
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Figure 2
Application of Crimean-Congo haemorrhagic fever molecular diagnostic methods, ENIVD survey, 2012 (n=23 laboratories)
ENIVD: European Network for Diagnostics of ‘Imported’ Viral Diseases; qRT-PCR: quantitative real-time reverse transcription polymerase chain 
reaction; RT-PCR: reverse transcription polymerase chain reaction.
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Finland, Hungary, Ireland, Luxembourg and Poland, 
corresponding to a participation of 76% of the coun-
tries and 45% of the laboratories. Of all laboratories 
that participated in the survey, 21 acted as a NRL for 
VHF and five act as a WHOCC.
Preparedness and response
All respondent laboratories declared that CCHF was a 
notifiable disease in their countries and that they fol-
lowed the generic case definition for VHFs, while six 
countries (Bulgaria, Greece, Germany, Turkey, Russia 
and Spain) had their own case definition for CCHF 
(Table 2).
Most laboratories (25/31) stated that they had trained 
staff authorised to handle CCHF samples and that there 
was trained staff in their countries skilled in assessing 
VHF cases/outbreaks; 19 laboratories emphasised a 
need for further training, not only for laboratory work-
ers, but also for medical and nursing staff. Half of the 
24 laboratories with CCHF diagnostic capacity stated 
their availability to offer training services for CCHF 
diagnosis to other laboratories in and outside their 
countries.
Of all responding laboratories, 20 had standardised 
procedures for specimen collection and storage of 
CCHF infected material, and 25 for processing and ship-
ping suspected CCHF specimens for confirmation diag-
nosis in other laboratories.
Diagnostic capacities
Of the 31 laboratories that participated in the survey, 
24 declared to have set up diagnostic capacities to 
detect CCHF infection. The remaining seven labora-
tories in countries where CCHF diagnostic capacities 
has not yet been established, declared that they were 
sending samples to reference laboratories or WHOCCs 
outside their countries (Figure 1).
Among the 24 laboratories with diagnostic capacities, 
all except the laboratory in Serbia had CCHF molecu-
lar tests based on either quantitative real-time reverse 
transcription polymerase chain reaction (qRT-PCR) or 
nested RT-PCR. Information on the type of commer-
cial or in-house protocol used was requested from 
the participants. Among the 23 laboratories which 
performed CCHF molecular diagnosis, 20 used an in-
house method, 11 used commercial assays and eight 
combined both in-house and commercial approaches 
(Figure 2).
The serological diagnosis of CCHFV infection is based 
on the detection of specific IgM and IgG antibodies 
against recombinant nucleoprotein as the predomi-
nant available antigen, either in an enzyme-linked 
immunosorbent assay (ELISA) or in an indirect immu-
nofluorescence assay (IFA). Most laboratories (22/24) 
with diagnostic capacities had available at least one 
serological technique, ELISA or IFA. Respondents were 
also asked about the availability of specific in-house 
or commercial (Vector-Best, Novosibirsk, Russia) 
ELISA tests for CCHF as well as in-house or commercial 
(EuroImmun, Luebeck, Germany) IFA (Table 2).
Eleven of 21 countries declared doing research to 
improve in-house molecular methods, and six of the 21 
declared investigating also new serological in-house 
methods.
Regarding quality assurance, this survey revealed 
that 19 of the 23 laboratories with molecular diagnos-
tic methods participated in the EQA on CCHF molecu-
lar diagnosis organised by ENIVD in 2011 [16], while 
only four participated in the exercise organised by 
the Quality Assurance exercise and Networking on the 
Detection of Highly Infectious Pathogens (QUANDHIP) 
project (www.quandhip.info) (Table 3).
Biosafety
The 24 laboratories with diagnostic capacities informed 
about the inactivation process before handling speci-
mens for diagnostic purpose. Among them, six labora-
tories inactivated specimens under BSL4, 12 in BSL3 
and five in BSL2 conditions (Figure 3). Of 11 labora-
tories performing viral isolation and propagation, six 
did so in BSL4 facilities and five in lower-grade BSL 
facilities.
Discussion
This survey has been carried out in 28 countries of the 
European region, including 10 countries where human 
cases are frequently or sporadically reported, or where 
there has been evidence of CCHFV circulation in ani-
mals or ticks. The presence of potential CCHFV vectors 
in other European countries may extend the current 
geographical distribution of the disease. In addition, 
imported cases in travellers have been reported in the 
EU. Hence, early recognition of the suspected CCHF 
cases is critical, in order to initiate the proper treat-
ment of the patient and to apply control measures for 
containment of the disease. Some authors argue that 
Europe needs to implement a harmonised case defi-
nition for CCHF in order to enhance notifications and 
to estimate the diseases burden and epidemiologi-
cal trends in various areas and countries [2]. The sur-
vey revealed that all responding countries used the 
generic case definition of VHFs to identify and notify 
CCHF cases. However, this survey has some limitations 
since not all responding countries clearly specified the 
source and reference of the generic or specific case 
definitions.
Networking and training are key factors in ensuring 
a rapid and effective response to CCHF. The survey 
revealed that the majority of countries belong to at 
least one network apart from ENIVD that could assure 
support, management, training in the diagnosis of 
CCHF cases, expert consultation, exchange of experi-
ences and protocols, and scientific support if needed. 
Considering that some respondents did not have pro-
cedures in place for specimen collection, processing or 
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transporting, the networks could also play a key role in 
closing this gap. The networks could also foster train-
ing via organising international workshops on CCHF 
diagnosis and biosafety.
Laboratory techniques are the cornerstone of CCHF 
diagnosis, essential for effective surveillance, manage-
ment of individual patients and outbreak prevention. 
In 2008, the multidisciplinary consultation of CCHF 
experts organised by ECDC showed that according to 
ENIVD, 15 of 27 countries performed CCHF diagnostics 
[13].The current survey launched in 2012 indicated an 
increase to 21 of 28 countries performing CCHF diag-
nostics. Our results show a strong increase in the 
diagnostic capacity for CCHF from 2008 to the present, 
possibly due to the nomination of CCHF as a priority 
disease for the EU. However, as shown in Table 1, two 
WHOCC next to endemic areas (Greece and Slovenia), 
lost their status as reference centres for VHF. This issue 
has to be taken in consideration when a new reference 
centre in Europe will be designated in the future.
Currently, the routine laboratory diagnosis of CCHF is 
based mainly on the detection of the viral genome and 
specific IgM and IgG. Most surveyed laboratories with 
diagnostic capacities (21/24) followed international 
recommendations of combining molecular and sero-
logical methods for CCHF diagnosis [1,28]. This shows 
that most of the surveyed laboratories have essential 
diagnostic tools for CCHF diagnosis in place.
Molecular assays offer a rapid, sensitive and specific 
diagnosis of CCHF during the viraemic phase of infec-
tion up to day 16 of illness [29]. The vast majority of 
surveyed countries (20/21) have molecular tests avail-
able, and most of them participated in CCHF EQAs. It is 
highly recommended that not only endemic countries, 
but also neighbouring countries that lack the capacity 
for molecular assays try to implement them.
Of the existing molecular methods for CCHF diagnosis, 
the majority of respondents (18/20) used a qRT-PCR, 
combined or not with nested PCR, while the remaining 
two countries used a nested RT-PCR only. Moreover, 
in a recent molecular EQA, it is reported that nested 
RT-PCR performs considerably less well compared with 
qRT-PCRs [16]. Therefore, it is recommended that coun-
tries performing only nested RT-PCR implement capaci-
ties for a quantitative assay because qRT-PCRs offer 
advantages when over nested RT-PCR such as lower 
contamination rate, higher sensitivity and specificity, 
and better time-effectiveness. A factor that may limit 
the use of molecular diagnostic methods is the fact 
that sensitivity may be affected by the high diversity 
of CCHF genomes. For instance, it has been found that 
sensitivity of molecular methods was associated with 
the patients’ country of origin [17]. A combination of 
commercial and in-house RT-PCR assays will probably 
ensure the detection of CCHFV strains despite their 
diversity. However, the survey reveals that 20 of 23 
laboratories use in-house RT-PCR but only eight com-
bine it with a commercial test.
Although serological methods may cover a broader 
spectrum of strains due to cross-reactivity, attention 
must be also paid to antigenic variation among CCHFV 
strains which may affect their sensitivity. However, 
combinations of ELISA and IFA, commercial or in-house, 
may increase the sensitivity of detection. A recent eval-
uation of two commercial kits (VectorBest ELISAs and 
Euroinmune IFA, both for IgM and IgG) revealed that 
efficient and well characterised serological assays and 
protocols are available for CCHF diagnosis [17]. Our 
survey reveals that all countries using the commercial 
ELISA also had available commercial IFAs and that half 
of them combined them with an in-house ELISAs that 
may compensate a potential lower sensitivity caused by 
antigenic diversity. We advise that each country assure 
that their methods are optimised for strains circulating 
in their area, or that they use an adapted method for 
CCHFV genotypes circulating in their country.
In addition, to assure that diagnostic methods perform 
with optimal accuracy, an increased effort is needed to 
establish EQA studies on a regular basis. In 2011, an 
international EQA for the molecular detection of CCHF 
was launched [16]. The majority of countries with areas 
endemic for or at risk of CCHF surveyed in our study 
Table 2
Application of Crimean-Congo haemorrhagic fever serological diagnostic methods, ENIVD survey, 2012 (n=22 respondents)
Serological diagnostic 
method Countries
Proportion of  countries (relative to 
those with CCHF serological tests)
Commercial assay Bulgaria, Latvia, Lithuania, the Netherlands, Portugal, Romania, Spain 37%
In-house assay France, Serbia, Sweden, Switzerland, United Kingdom 26%
Commercial and in-house 
assay
Germany, Greece, Kosovo under UN Security Council Resolution 1244, 
Italy, Russia, Slovenia, Turkey 42%
CCHF: Crimean-Congo haemorrhagic fever; ELISA: enzyme-linked immunosorbent assay; ENIVD: European Network for Diagnostics of 
‘Imported’ Viral Diseases; IFA: indirect immunofluorescence assay..
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Table 3
Laboratory preparedness and response capacities for Crimean-Congo haemorrhagic fever diagnosis in the European region, 
ENIVD survey, 2012 (n=28 countries)
Countries
Preparedness and response Diagnostic methods
Case definition
Networks
EQA
Diagnostic techniques BSLGeneric 
VHFf
Specific 
CCHF ENIVD QUANDHIP
Austria  Yes No ENIVD Yes No PCR BSL2+
Belgium  NA No ENIVD No No Referral  
Bulgaria  NA Yesa ENIVD, EpiSouth, CCH-FEVER Yes No PCR, ELISA, IFA, VI BSL2
Croatia Yes Yesa ENIVD No No PCR BSL3
Czech Republic  NA No ENIVD No No Referral  
Estonia Yes No ENIVD No No Referral
Former Yugoslav 
Republic of 
Macedonia
 NA Yesb ENIVD, EpiSouth No No Referral  
France  NA No ENIVD, EpiSouth, Euronet-P4 Yes (Lyon) No PCR, ELISA, VI BSL4
Germany  NA Yes ENIVD, Euronet-P4 Yes (Hamburg) Yes PCR, ELISA, IFA, VI BSL4
Greece  NA Yesc ENIVD, EpiSouth, Arbo-Zoo-net, CCH-FEVER Yes No PCR, ELISA, IFA, VI BSL3
Italy  NA No ENIVD, EpiSouth, Euronet-P4 Yes Yes PCR, IFA, VI BSL4
Kosovo under UN 
Security Council 
Resolution 1244
 NA Yes ENIVD, EpiSouth No No PCR, ELISA, IFA BSL2
Latvia  NA Yes ENIVD Yes No PCR, IFA BSL3
Lithuania  NA No ENIVD No No PCR, IFA, VI BSL3
Malta Yes (ECDC) No ENIVD, EpiSouth No No Referral  
The Netherlands Yes No ENIVD Yes No PCR, IFA BSL3
Norway Yes No ENIVD No No Referral  
Portugal  NA No ENIVD Yes No PCR, ELISA, IFA BSL3
Romania Yes No ENIVD, EpiSouth Yes No PCR, IFA BSL2
Russia No Nod ENIVD Yes No PCR, ELISA, IFA BSL3
Serbia Yes Yesa ENIVD, EpiSouth No No IFA, VI BSL2
Slovakia No No ENIVD No No Referral  
Slovenia Yes No ENIVD, CCH-FEVER, Arbo-Zoo-Net Yes No PCR, ELISA, IFA, VI BSL3+
Spain Yes Yese ENIVD, EpiSouth Yes No PCR, IFA BSL3
Sweden Yes No ENIVD, CCH-FEVER, Euronet-P4, Arbo-Zoo-Net Yes Yes PCR, IFA, VI BSL4
Switzerland Yes Yes ENIVD Yes No PCR, ELISA BSL4
Turkey  NA Yes ENIVD, EpiSouth, CCH-FEVER Yes No PCR, ELISA, IFA BSL3
United Kingdom Yes No ENIVD, Euronet-P4 Yes (Porton Down) Yes PCR, ELISA, IFA, VI BSL4
Arbo-Zoo-Net: Network for Capacity Building for the Control of Emerging Viral Vector Borne Zoonotic Diseases; BSL: biosafety level; CCH-FEVER: 
Crimean Congo Haemorrhagic Fever Network; ECDC: European Centre for Disease Prevention and Control; ELISA: enzyme-linked immunosorbent 
assay; ENIVD: European Network for Diagnostics of ‘Imported’ Viral Diseases; EpiSouth: Network for Communicable Disease Control in Southern 
Europe and Mediterranean Countries; Euronet-P4: European Network of Biosafety-Level-4 laboratories; EQA: external quality assessment; IFA: 
indirect immunofluorescence assay; NA: not available; PCR: polymerase chain reaction; QUANDHIP: Quality Assurance exercise and Networking 
on the Detection of Highly Infectious Pathogens project; VHF: viral haemorrhagic fever; VI: viral isolation. 
a  [22,23].
b  National guides in preparation.
c  [24].
d Not formal case definition [25].
e  [26]
f  EU case definition for VHF [27].
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also participated in this EQA, in which 53 datasets 
were received from 44 laboratories worldwide, mostly 
European. Twenty of the datasets (38%) met the crite-
ria with optimal performance.
The most definite way of CCHF diagnosis is detection of 
viral RNA combined with detection of IgM antibodies. 
Virus isolation as a diagnostic tool is rarely applied 
because high biocontainment laboratories (BSL4) are 
required. None of the European BSL4 laboratories are 
situated in CCHF areas, and among 11 laboratories per-
forming viral propagation, five reported that they do 
not work in BSL4 facilities. Three of these five labora-
tories were in CCHF endemic countries.
In conclusion, the main priority issues to be addresses 
by European health authorities are: (i) establishing 
rapid and reliable protocols for CCHF laboratory diag-
nosis together with guidelines on storage, process-
ing and transportation of samples, (ii) nominating a 
Regional Reference Expert Laboratory or a WHOCC in 
or near the endemic areas, and (iii) a comprehensive 
review of the BSL facilities suited to the reality in the 
endemic areas, their capacities and capabilities.
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Capobianchi at National Institute for Infectious Diseases 
“L.Spallanzani”, Laboratory of Virology, Rome. Kosovo un-
der UN Security Council Resolution 1244: Xhevat Jakupi at 
National Institute of Public Health of Kosovo, Department of 
Microbiology. Latvia: Jelena Storozenko at Infectology Center 
of Latvia, National Microbiology Reference Laboratory. 
Lithuania: Algirdas Griskevicius at National Public Health 
Surveillance Laboratory, Molecular Biology Testing 
Subdivision. Former Yugoslav Republic of Macedonia: 
Golubinka Bosevska at Institute of Health Protection of RM, 
Laboratory for virology and molecular diagnosis. Malta: 
Clive Muscat at Mater Dei Hospital, Virology Laboratory. 
The Netherlands: Martin Schutten at Erasmus University 
Hospital Rotterdam, Department of Virology. Norway: 
Susanne Dudman at Norwegian Institute of Public Health, 
Department of Virology, Oslo. Portugal: Maria Joao Alves at 
National Institute of Health, Centre for Vectors and Infectious 
Diseases Research, Águas de Moura. Romania: Cornelia 
Ceianu at National Institute of Public Health, National Center 
for Surveillance and Control of Communicable Diseases, 
Lab For Vector Borne Infections and Medical Entomology, 
Bucharest. Russia: Alexander Platonov at Central Research 
Institute of Epidemiology, Laboratory for zoonoses, Moscow. 
Serbia: Bojana Bozovic at Torlak Institute of Virology, 
Vaccines and Sera, National Reference Laboratory for 
Arboviruses. Slovakia: Boris Klempa at Institute of virology, 
Figure 3
Biosafety levels for laboratories with Crimean-Congo 
haemorrhagic fever diagnostic capacities, ENIVD survey, 
2012 (n=24)
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Slovak Academy of Sciences, Department of Virus Ecology. 
Slovenia: Tatjana Avsic at University of Ljubljana, Laboratory 
for diagnosis of zoonoses. Spain: Antonio Tenorio at 
Instituto de Salud Carlos III, Laboratory of Arbovirus and 
Imported Viral Diseases, Majadahonda, Madrid. Sweden: 
Ake Lundkvist at Swedish Institute for Infectious Disease 
Control, Karolinska Institute Stockholm, Solna. Switzerland: 
Pascal Cherpillod at University Hospitals of Geneva, 
Laboratory of Virology. Turkey: Gulay Korukluoglu at Refik 
Saydam Hygiene Institute, Department of Virology, Ankara. 
United Kingdom: David Brown at Virus reference depart-
ment, Public Health England, Colindale and Tim Brooks at 
Special Pathogens Reference Unit. Public Health England, 
Porton Down.
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